Replies to post #28849 on Ariad Pharmaceuticals Inc fka ARIA

[jaybe]

The most comprehensive guidelines come from NCCN...

Also referenced on page 3 of the RengenceRx piece.

See link for summary of NCCN guidelines, check out page 12, where Pona is recommended first for all mutuations. Ponatinib summary on pages 20-26. I like the summary slide, page 26, "[Ponatinib is]expected to significantly improve outcomes of CML and Ph+ ALL".

(By the way if you want to see what a dirty drug profile looks like check out Bosutinib on page 16.)


https://winshipcancer.emory.edu/media/file/2013%20Nursing%20Symposium/Nikki%20Wilson%20-%20Novel%20Therapies%20for%20the%20Treatment%20of%20Multiple%20Myeloma%20and%20Leukemia.pdf